Strategy& works with respected global, regional and
specialty pharmaceutical companies, biotech, OTC health, diagnostic
and medical device companies worldwide.
We bring a truly differentiated ability to not only develop
strategy, but also help deliver value, build and embed new
capabilities, and effect change. We combine deep functional
expertise in strategy, operations, information technology, and
organization with a unique strategic perspective based on our
leading position working across the health system, with health
plans and providers as well as life sciences companies.
Whether helping clients tackle a key strategic issue, answer a
growth question, deepen functional capabilities or strengthen how
they run their organization our true north remains the same:
building essential advantage.
Five key trends & required capabilities for life sciences companies >
Our thought leadership
The emergence of new technologies could convince physicians and insurers that patient-specific healthcare is here to stay.
Animal health businesses can thrive within human pharma organizations. But only if their leadership is permitted to tailor their businesses to the unique demands of the animal health market.
In the post-reform healthcare environment, pharmaceutical companies have a clear opportunity to play a greater role in delivering a better experience for patients, improving clinical outcomes, and reducing the total cost of care.
Medtech companies must take the right strategic approach to managing costs while investing in capabilities and growth initiatives, via a Fit for Growth transformation.
The business model that drove the major drugmakers’ success isn’t working anymore. The survivors will be those that make smart strategic bets supported by winning capabilities.
For decades the pharmaceutical industry’s direct-to-physician marketing model worked extremely well.
More successful pharmaceutical companies are adopting analytical techniques to identify and capture precious points of profitable market share.
To better understand both the challenges faced by the global pharmaceutical industry in its pursuit of emerging-market opportunities and the strategies that leaders are employing to address them.
The days of the disengaged health consumer are numbered. Consumerization will transform healthcare systems, involving individuals as never before in the management of their own care.
Breakthroughs in pharmaceutical innovation are poised to change the prevailing business model of the industry — with dramatic effects on healthcare costs and practice.
Global drug companies are facing disruption. One powerful strategic response is to rethink their manufacturing and operations footprints.
read more health thought leadership >
see all >
A global pharmaceutical company had recently reorganized into new lines of business and needed a business unit-specific strategy for winning in its defined markets. The client had a history of working in independent and autonomous therapeutic areas and regional leaders were skeptical about the added value of the new business line structure.
A pharmaceutical company was struggling to grow revenues for several key primary care products by tapping into ‘lost patients’ that fell out of the diagnosis/treatment/fulfilment pathway. Strategy& was engaged to analyze the market opportunity, identify critical “pain points” and characterize value capture opportunities which could be addressed by digital solutions.
A global pharmaceutical company wanted to step up its position in personalized medicine, including more strategic use of companion diagnostics to drive the value of its drug portfolio.
read more >
Within the life sciences sector, our specific service areas include:
Marketing and sales
Organization, change and leadership
Research and development
Business model innovation
Technology strategy and IT effectiveness
Mergers and restructuring
G&A functional excellence